Immunotherapy Coverage from Every Angle

Recent News

ASCO 2022: Combination Therapy With Umbilical Cord Blood–Derived Natural Killer Cells for Myeloma
ASCO 2022: Mobocertinib Versus Amivantamab-vmjw in Treatment of EGFR-Mutated NSCLC
Cemiplimab-rwlc in Squamous Cell Carcinoma of the Skin: Living in the Real World
Lisocabtagene Maraleucel Approved by FDA in Second-Line Treatment of LBCL
ASCO 2022: Eftilagimod Alpha Plus Pembrolizumab in NSCLC
ASCO 2022: Phase II MagnetisMM-3 Trial Focuses on Elranatamab in Resistant Myeloma
ASCO 2022: Amivantamab-vmjw Under Study in NSCLC With Primary MET Exon 14 Skipping Mutation
ASCO 2022: PD-1 Inhibitory–Refractory Merkel Cell Carcinoma: Is T-Cell Therapy a Step in the Right Direction?
ASCO 2022: Tislelizumab Plus Nab-Paclitaxel Under Study in Urothelial Bladder Cancer
ASCO 2022: Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Follicular Lymphoma
Baseline Body Mass Index and Outcomes in Chemoimmunotherapy-Treated Lung Cancer
After CAR T-Cell Therapy for Diffuse Large B-Cell Lymphoma: What’s Next?
ASCO 2022: Update From Cohort A of CARTITUDE-2 on Ciltacabtagene Autoleucel in Myeloma
ASCO 2022: Updated Safety Data From DESTINY-Breast03 on T-DXd Versus T-DM1 in Metastatic Breast Cancer
ASCO 2022: COSMIC-021 Cohorts of Cabozantinib Plus Atezolizumab in Urothelial Cancer
EHA 2022: Patient-Reported Outcomes With Lisocabtagene Maraleucel in LBCL
ASCO 2022: Ixazomib Plus Daratumumab in Elderly Frail Patients With Resistant Multiple Myeloma
ASCO 2022: 2-Year Follow-up on Enfortumab Vedotin for Urothelial Cancer
ASCO 2022: Adjuvant Cemiplimab-rwlc Under Study in High-Risk Cutaneous Squamous Cell Carcinoma
EHA 2022: Preliminary Data From PACIFIC Trial of Nivolumab Plus Brentuximab Vedotin in LBLC
ASCO 2022: Novel HER3-Directed Antibody-Drug Conjugate Under Study in Metastatic Breast Cancer
ASCO 2022: CHRYSALIS-2 Update on Amivantamab-vmjw Plus Lazertinib in NSCLC
EHA 2022: Fixed Duration of Bispecific Antibody Glofitamab in Resistant DLBCL
ASCO 2022: Early-Phase Study of Talquetamab in Resistant Multiple Myeloma
ASCO 2022: Pathologic Regression and Event-Free Survival With Nivolumab Plus Chemotherapy for NSCLC
ASCO 2022: Immunotherapy Followed by Cetuximab for Advanced Cutaneous Squamous Cell Carcinoma
ASCO 2022: Extended Follow-up With Obinutuzumab, Ibrutinib, and Venetoclax in CLL
ASCO 2022: 3-Year Follow-Up From ZUMA-2 Trial of KTE-X19 in Resistant Mantle Cell Lymphoma
ASCO 2022: 3-Year Trial Update on Nivolumab Plus Ipilimumab and Chemotherapy for Metastatic NSCLC
ASCO 2022: Update From CARTITUDE-1 on Ciltacabtagene Autoleucel in Refractory Myeloma
ASCO 2022: Oncolytic Virus Plus Cemiplimab-rwlc Under Study in Cutaneous Squamous Cell Cancer
ASCO 2022: DESTINY-Breast04 Reports Benefit of T-DXd in HER2-Low Metastatic Breast Cancer
ASCO 2022: Second-Line Pembrolizumab Plus Ramucirumab in Advanced NSCLC
ASCO 2022: Neoadjuvant Targeting of PD-1 Plus SBRT in Muscle-Invasive Bladder Cancer
ASCO 2022: TROPiCS-02 Meets Study Endpoint With Sacituzumab Govitecan-hziy in Advanced Breast Cancer
ASCO 2022: Does Dosing Frequency and Duration of Anti–PD-1 Therapy Impact Outcomes in Skin Cancers?
ASCO 2022: Neoadjuvant Enfortumab Vedotin-ejfv in Cisplatin-Ineligible Bladder Cancer
ASCO 2022: Ibrutinib Plus Chemoimmunotherapy in Older Patients With Mantle Cell Lymphoma
Novel Triplet Under Study in Advanced Immunomodulatory Triple-Negative Breast Cancer
Phase II ZUMA-12 Trial Evaluates First-Line Use of Axicabtagene Ciloleucel in High-Risk LBCL
Predicting Remission With CAR T-Cell Therapy in Large B-Cell Lymphoma: Focus on FDG-PET Imaging
Can Immune Checkpoint Inhibitors Improve Pathologic Complete Response in Breast Cancer?
IMpower150 Mutational Subgroup Analysis of Chemoimmunotherapy for KRAS-Mutated Lung Cancer
Trial of Intravesicular Adenovirus Vector Therapy in Bladder Cancer Unresponsive to BCG
Vaccine Plus Co-stimulated T Cells Under Study in Multiple Myeloma
Can Addition of T-DM1 Improve Outcomes Over Standard Treatment in HER2-Positive Breast Cancer?

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.